New Warnings Required for Gadolinium-Based Contrast Agents

Share this article:

The FDA is requiring that gadolinium-based contrast agents (GBCAs) carry new warnings on their labels about the risk of nephrogenic systemic fibrosis (NSF) if administered to certain patients with kidney disease.

Three GBCAs—Magnevist, Omniscan, and Optimark—will be described as inappropriate for use among patients with acute kidney injury or chronic severe kidney disease, according to the FDA. All GBCA labels will emphasize the need to screen patients to detect these types of kidney problems prior to administration.

NSF is a condition involving the formation of excess fibrous connective tissue in the skin, joints, eyes, and internal organs. Symptoms can include scaling, hardening and tightening of the skin, red or dark patches on the skin, and stiffness. NSF can lead to death, particularly if it involves organs, the FDA said.

Share this article:
You must be a registered member of RUN to post a comment.
close

Next Article in Acute Kidney Injury

More in Acute Kidney Injury

Stroke Risk Higher in Patients Who Recover from AKI

Stroke Risk Higher in Patients Who Recover from ...

Taiwan study reveals a 25% increased risk of stroke among patients who recover from dialysis-requiring acute kidney injury.

Statins May Lower Risk of Contrast-Induced AKI

Statins May Lower Risk of Contrast-Induced AKI

Meta-analysis reveals a 46% decreased risk of contrast-induced acute kidney injury in patients undergoing coronary catheterization.

Where AKI Develops Affects Death Risk

Where AKI Develops Affects Death Risk

Patients are more likely to die if their acute kidney injury was acquired in the hospital rather than in the community.